212 related articles for article (PubMed ID: 17908970)
1. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.
Bachmann HS; Otterbach F; Callies R; Nückel H; Bau M; Schmid KW; Siffert W; Kimmig R
Clin Cancer Res; 2007 Oct; 13(19):5790-7. PubMed ID: 17908970
[TBL] [Abstract][Full Text] [Related]
2. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.
Hirata H; Hinoda Y; Nakajima K; Kikuno N; Suehiro Y; Tabatabai ZL; Ishii N; Dahiya R
J Urol; 2009 Aug; 182(2):721-7. PubMed ID: 19539330
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases.
Olopade OI; Adeyanju MO; Safa AR; Hagos F; Mick R; Thompson CB; Recant WM
Cancer J Sci Am; 1997; 3(4):230-7. PubMed ID: 9263629
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
[TBL] [Abstract][Full Text] [Related]
6. Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.
Fingas CD; Katsounas A; Kahraman A; Siffert W; Jochum C; Gerken G; Nückel H; Canbay A
Cancer Invest; 2010 Jun; 28(5):472-8. PubMed ID: 19968497
[TBL] [Abstract][Full Text] [Related]
7. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
9. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.
El Hindy N; Bachmann HS; Lambertz N; Adamzik M; Nückel H; Worm K; Zhu Y; Sure U; Siffert W; Sandalcioglu IE
J Neurosurg; 2011 Jun; 114(6):1631-9. PubMed ID: 21250804
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
[TBL] [Abstract][Full Text] [Related]
11. bcl-2 and apoptosis in lymph node positive breast carcinoma.
Berardo MD; Elledge RM; de Moor C; Clark GM; Osborne CK; Allred DC
Cancer; 1998 Apr; 82(7):1296-302. PubMed ID: 9529021
[TBL] [Abstract][Full Text] [Related]
12. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression.
Hughes S; Agbaje O; Bowen RL; Holliday DL; Shaw JA; Duffy S; Jones JL
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6673-80. PubMed ID: 18006768
[TBL] [Abstract][Full Text] [Related]
14. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Kelava A; Nückel H; Lang S; Schmid KW; Siffert W; Bachmann HS
Ann Oncol; 2009 Jun; 20(6):1094-9. PubMed ID: 19196738
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
16. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
Hirata H; Hinoda Y; Kikuno N; Suehiro Y; Shahryari V; Ahmad AE; Tabatabai ZL; Igawa M; Dahiya R
J Urol; 2009 Apr; 181(4):1907-12. PubMed ID: 19237173
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer.
Bica CG; da Silva LL; Toscani NV; Zettler CG; Gottlieb MG; Alexandre CO; Graudenz MS; Mânica da Cruz IB
Cancer Genet Cytogenet; 2010 Jan; 196(2):153-8. PubMed ID: 20082851
[TBL] [Abstract][Full Text] [Related]
18. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
Watari H; Ohta Y; Hassan MK; Xiong Y; Tanaka S; Sakuragi N
Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
[TBL] [Abstract][Full Text] [Related]
19. Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.
Bhushann Meka P; Jarjapu S; Vishwakarma SK; Nanchari SR; Cingeetham A; Annamaneni S; Mukta S; Triveni B; Satti V
Tumour Biol; 2016 May; 37(5):6905-12. PubMed ID: 26662799
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
